A broad device portfolio is dull until one product stumbles

Owning dozens of product lines across cardiology, surgery and diabetes looks unexciting next to a single-product growth story. The value of breadth shows up when a single product runs into a recall, a competitor or a reimbursement cut.

Breadth as insurance

A diversified device maker rarely has a quarter where everything goes right, and rarely one where everything goes wrong. Problems in one franchise are diluted by the others. The cost is growth: a large, broad company has to add a lot of new revenue to move its growth rate at all.

When new products do come through, they arrive with the distribution, the hospital relationships and the service network already in place.

What I'm watching

• Organic growth across the major franchises
• New product launches in the faster-growing categories
• Margin recovery after supply chain pressures

Where I stand

Long, on breadth plus a handful of faster-growing launches. The portfolio does not need a breakthrough, only fewer drags.

What would change my mind

Growth that depends on one or two launches while the rest of the portfolio shrinks. That would turn the insurance into a hidden concentration.